Nicotinamide adenine dinucleotide (NAD⁺) is not a peptide. It is a coenzyme found in every living cell, essential for over 500 enzymatic reactions involved in energy metabolism, DNA repair, gene expression regulation, and cellular signaling. NAD⁺ exists in oxidized (NAD⁺) and reduced (NADH) forms and serves as a critical electron carrier in glycolysis, the Krebs cycle, and mitochondrial oxidative phosphorylation.
The relevance of NAD⁺ to longevity and metabolic medicine stems from a well-documented observation: intracellular NAD⁺ levels decline significantly with aging across multiple tissues (skin, blood, liver, muscle, brain). This decline is associated with reduced sirtuin activity, impaired DNA repair (PARP function), mitochondrial dysfunction, and the metabolic deterioration characteristic of aging. The hypothesis driving the field is that restoring NAD⁺ levels could reverse or delay age-related functional decline.
Because NAD⁺ itself has poor oral bioavailability, supplementation strategies focus on precursors that cells can convert to NAD⁺ through biosynthetic pathways. The two primary precursors are nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Both have been shown in multiple human randomized controlled trials to safely raise blood NAD⁺ levels. IV NAD⁺ infusions are also available at specialized clinics, bypassing the oral absorption question entirely.
Evidence context: NAD⁺ biology is one of the most active areas of aging research, with legitimate scientific foundations. Multiple human RCTs confirm that NMN and NR safely increase NAD⁺ levels. However, whether raising NAD⁺ levels translates to clinically meaningful anti-aging benefits in humans remains unproven. The gap between "increases a biomarker" and "extends healthspan" has not been bridged by the clinical data available as of 2026.
| Weeks | Dosage | Syringe units (U-100) |
|---|---|---|
| Week 1 | 50 mg | 50 units0.5 mL |
| Week 2 | 75 mg | 75 units0.75 mL |
| Weeks 3–16 | 100 mg | 100 units1 mL |
| Weeks | Dosage | Syringe units (U-100) |
|---|---|---|
| Week 1 | 50 mg | 25 units0.25 mL |
| Week 2 | 75 mg | 37.5 units0.38 mL |
| Weeks 3–16 | 100 mg | 50 units0.5 mL |
FrequencyOnce daily, subcutaneous.
For review — the human evidence is for oral precursors. The trials cited on this page studied NMN and nicotinamide riboside taken by mouth, not injected NAD+; the rows in the chart follow a circulated research protocol. The concentration strip above the chart is calculated from the vial and water volume and is correct.
Unverified — no trial establishes an injected frequency for NAD+ itself.
The randomised trials behind NAD+ studied its oral precursors — NMN at 250 to 900 mg a day and nicotinamide riboside at 1,000 to 2,000 mg a day — and precursor dosing does not convert into an amount of NAD+ itself, so the injected schedule charted here is flagged for review rather than presented as established. Injected and infused NAD+ is widely offered without a dose-ranging trial establishing an amount, a rate or a schedule; the discomfort commonly reported with infusions is a function of how fast it goes in rather than how much, which is a distinction a weekly chart cannot show. Both vials take the same 5 mL of bacteriostatic water, so the 500 mg strength comes to 100 mg/mL and the 1,000 mg strength to 200 mg/mL, and the volume drawn is not the same on the two charts. From the 500 mg vial the 50 mg opening step is exactly one full 50-unit syringe, and the 75 mg and 100 mg steps are 75 and 100 units — more than that syringe holds, so they are marked. From the 1,000 mg vial the same three amounts are 25, 37.5 and 50 units, every one of them inside a single 50-unit fill.
Measurement note. At this strength and water volume one or more of the amounts above is larger than the 0.5 mL a 50-unit U-100 syringe holds, so it would be drawn with a 100-unit syringe rather than in a single 50-unit fill.
What this evidence establishes. The human dosing evidence is for the oral precursors NMN and NR, not for NAD+ itself. Injected and infused NAD+ is widely offered but has no dose-ranging trial establishing an amount, a rate or a schedule, and the infusion discomfort commonly reported is rate-dependent rather than dose-dependent. Precursor dosing does not convert to an NAD+ dose.
Sources: NMN randomised controlled trials, up to 12 weeks · NR randomised controlled trials, up to 60 days (GeroScience, 2024 and others)
For educational and laboratory research purposes only. It does not provide medical advice, dosing recommendations, or instructions for human or veterinary use. Syringe units assume a U-100 syringe, on which 1 mL is 100 units and a 50-unit syringe holds 0.5 mL.
NAD⁺ functions through three major downstream pathways, plus its role as a metabolic cofactor:
Essential electron carrier in glycolysis, Krebs cycle, and oxidative phosphorylation. Without NAD⁺, cells cannot produce ATP through aerobic metabolism.
NAD⁺ is the obligate co-substrate for sirtuins, a family of deacetylases that regulate gene expression, inflammation, stress resistance, and longevity pathways.
NAD⁺ is consumed by poly(ADP-ribose) polymerases (PARPs) during DNA damage repair. PARP activation depletes cellular NAD⁺ pools, creating competition with sirtuin pathways.
NAD⁺ is consumed by CD38 (cyclic ADP-ribose hydrolase) for calcium signaling. CD38 expression increases with age and is a major driver of age-related NAD⁺ decline.
The primary NAD⁺ biosynthesis route: NAMPT converts nicotinamide to NMN, then NMNAT converts NMN to NAD⁺. NAMPT is the rate-limiting enzyme and declines with age.
NMN and NR bypass the rate-limiting NAMPT step via NRK-mediated conversion. Both have been shown to raise blood NAD⁺ levels in human RCTs within days to weeks.
NAD⁺ precursors (NMN, NR) have the most extensive human safety data of any compound profiled on this site that is not FDA-approved as a drug. Multiple RCTs demonstrate good tolerability:
| Condition / Factor | Risk Level | Rationale |
|---|---|---|
| Active cancer | HIGH (theoretical) | NAD⁺ is required for rapid cell proliferation. Sirtuins have context-dependent roles in cancer biology. Raising NAD⁺ in the presence of active malignancy could theoretically support tumor metabolism. Not studied in cancer patients. |
| Pregnancy / breastfeeding | MODERATE (limited data) | NAD⁺ is a normal metabolic component, but effects of supraphysiological NAD⁺ precursor doses on fetal development have not been specifically studied. |
| GI side effects (high-dose NR) | LOW | High-dose NR (>1000 mg/day) can cause mild GI discomfort, nausea, and skin flushing (niacin-like). Generally transient and well-tolerated. |
| IV NAD⁺ infusion reactions | MODERATE | IV NAD⁺ can cause chest tightness, nausea, headache, and abdominal cramping during infusion. Rate-dependent. Typically managed by slowing infusion rate. |
| Drug interactions (limited data) | LOW (but understudied) | No significant drug interactions identified in published RCTs. However, formal drug-drug interaction studies are limited. |
| NMN regulatory status (US) | MODERATE (regulatory) | FDA determined in 2023 that NMN cannot be marketed as a dietary supplement in the US. Legal status for NMN supplements is in flux. NR remains available as a supplement. |
| Individual response variability | LOW (expected) | NAD⁺ response to supplementation varies based on genetics, gut microbiome, baseline NAD⁺ status, and lifestyle factors. Some individuals may not respond to standard doses. |
| Long-term safety (>1 year) | MODERATE (limited data) | Most RCTs are 4-16 weeks in duration. Long-term safety data (>1 year) is limited. Chronic effects of sustained supraphysiological NAD⁺ levels are unknown. |
| Short-term safety (RCT data) | FAVORABLE | Multiple RCTs demonstrate NMN and NR are well-tolerated at doses up to 2000 mg/day for up to 60 days. No serious adverse events attributed to NAD⁺ precursors in published trials. |
| Proven anti-aging efficacy | UNPROVEN | NAD⁺ precursors reliably raise blood NAD⁺ levels. Whether this translates to clinically meaningful anti-aging, longevity, or healthspan benefits in humans remains undemonstrated by current evidence. |
FDA: No NAD⁺ precursor is FDA-approved as a drug for any disease. NR (nicotinamide riboside) has Generally Recognized as Safe (GRAS) status and is sold as a dietary supplement. NMN's supplement status is contested following the FDA's 2023 determination that NMN was first investigated as a drug, though it remains widely sold. IV NAD⁺ is administered at clinics as an off-label practice.
Supplement Landscape: NR is sold under brand names including Niagen (ChromaDex/Tru Niagen) and is the most extensively studied NAD⁺ precursor in human trials. NMN is sold by numerous supplement brands globally. Direct NAD⁺ supplements also exist but have poor oral bioavailability.
Key distinction: NAD⁺ biology is real, important, and well-supported by decades of biochemistry research. The age-related decline in NAD⁺ is well-documented. The ability of NMN and NR to raise NAD⁺ levels is confirmed by multiple RCTs. However, the critical question remains unanswered: does raising NAD⁺ levels in humans produce clinically meaningful health benefits? The preclinical data (dramatic lifespan extension in model organisms) has not yet been replicated in human outcome studies. NAD⁺ supplementation is a scientifically grounded hypothesis, not a proven therapy.
Test your understanding of NAD⁺ metabolism, precursor science, and the current state of clinical evidence.
This profile is for educational and research purposes only. It is not medical advice, and nothing on it is a protocol, a recommendation, or an instruction for use in a person or an animal.
Athena Peptides Education does not prescribe, sell, or recommend any compound. Compounds discussed here are for laboratory research only and are not for human consumption. Always consult a qualified physician before making any decision about your health.